fda bpc-157 safety risks compounding Issues Warning: Certain Bulk Drug Substances May Pose Major Legal and Patient FDA mulls compounding for peptides

Levine, M., Rumsey, S

[DOI] [PMC free article] [PubMed] [Google Scholar] 851

5 days/week (~12 mg/day): ~13 vials 3/week (2 mg): ~12 vials 16 weeks: ~3 vials Insulin Syringes (U-100, 1 mL) Per injection: 1 syringe 8 weeks (5 days/week): ~40 syringes 16 weeks (5 days/week): ~80 syringes Bacteriostatic Water (10 mL bottles) Use ~3.0 mL per 100 mg vial for reconstitution

BPC-157 may not be appropriate when: Imaging or specialist review has not yet been completed for a suspected structural injury There are acute red flag features (severe weakness, fever, rapid unexplained swelling, neurological changes, unexplained weight loss) The patient has active cancer or a history of certain cancers where angiogenic peptides require careful risk assessment The goal is rapid results without addressing underlying load, rehabilitation, or lifestyle drivers A peptide should not be used to delay evaluation that is clearly warranted